Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

Trial Profile

Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs T-lymphocyte cell therapy (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TC BioPharm
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 13 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top